Frencken Group - UOB Kay Hian 2023-08-15: Stable Outlook Expected For 2H23; Upgrade To BUY

• Frencken’s 1H23 earnings of S$12m (-54% y-o-y) is in line with expectation, accounting for 46% of our full-year estimate. 1H23 revenue fell 9% y-o-y as all segments saw revenue declines, with the exception of medical (+29% y-o-y) and analytical & life sciences (+7% y-o-y).
• - Read this at SGinvestors.io -
• We raise our target price for Frencken by 28% to S$1.00 after rolling over our valuation base year. Upgrade Frencken to BUY.

1H23 earnings of S$12m (-54% y-o-y) was in line with expectation.

• - Read this at SGinvestors.io -

Revenue declined across four segments, while that for medical and analytical & life sciences rose.

• Read more at SGinvestors.io.

Above is an excerpt from a report by UOB Kay Hian Research.
Clients of UOB Kay Hian may be the first to access the full PDF report @ https://www.utrade.com.sg/.

Read also UOB's most recent report:
2025-11-18 Frencken - Outlook For 2H25 Downgraded Due To Semiconductor Softness.

Previous report by UOB:
2025-08-18 Frencken - 1H25 Results In Line; Expect Stable Outlook For 2H25.

Price targets by 2 other brokers at Frencken Target Prices.

Listing of research reports at Frencken Analyst Reports.

Relevant links:
Frencken Share Price History,
Frencken Announcements,
Frencken Dividend Payout Dates & Corporate Actions,
Frencken News